IGC insider transaction filings
IGC Pharma, Inc. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-01. Screen IGC transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| GRIMALDI CLAUDIA — PFO, Director | 1 | — | — | 1 |
| Mukunda Ram — CEO, Director | 1 | — | — | 1 |
Recent Form 4 filings — IGC Pharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | GRIMALDI CLAUDIA — PFO, Director | Grant/award (A): 2,048,378 @ $0.27 | EDGAR |
| 2026-07-01 | 4 | Mukunda Ram — CEO, Director | Grant/award (A): 2,226,475 @ $0.27 | EDGAR |
| 2026-04-06 | 4 | Moran James P — Director | Option exercise (M): 80,000 @ $0 · Option exercise (M): 50,000 @ $0 · Option exercise (M): 80,000 (derivative) @ $0 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | GRIMALDI CLAUDIA — PFO, Director | Option exercise (M): 100,000 @ $0 · Option exercise (M): 138,462 @ $0.26 · Option exercise (M): 100,000 (derivative) @ $0 · Option exercise (M): 138,462 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | PRINS RICHARD K — Director | Option exercise (M): 100,000 @ $0 · Option exercise (M): 70,000 @ $0 · Option exercise (M): 100,000 (derivative) @ $0 · Option exercise (M): 70,000 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Mukunda Ram — CEO, Director | Option exercise (M): 333,333 @ $0 · Option exercise (M): 323,077 @ $0.26 · Option exercise (M): 16,667 @ $0 · Option exercise (M): 33,332 @ $0 · Option exercise (M): 333,333 (derivative) @ $0 · Option exercise (M): 323,077 (derivative) @ $0 · +2 more | EDGAR |
| 2026-02-04 | 4 | Mukunda Ram — CEO, Director | Option exercise (M): 50,000 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 · Grant/award (A): 66,666 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | PRINS RICHARD K — Director | Option exercise (M): 100,000 @ $0 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-10-22 | 4 | PRINS RICHARD K — Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | Moran James P — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | LIERMAN TERRY L — Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | GRIMALDI CLAUDIA — PFO, Director | Gift (G): 50,000 @ $0 · Grant/award (A): 1,000,000 (derivative) @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | Mukunda Ram — CEO, Director | Gift (G): 100,000 @ $0 · Grant/award (A): 3,000,000 (derivative) @ $0 · Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
| 2024-09-27 | 4 | Moran James P — Director | Purchase (P): 588,235 @ $0.34 | EDGAR |
| 2024-08-12 | 4 | PRINS RICHARD K — Director | Gift (G): 200,000 @ $0 | EDGAR |
| 2024-05-13 | 4 | Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857) — 10% owner | Grant/award (A): 8,823,529 @ $0.34 | EDGAR |
| 2024-03-18 | 4 | MUKUNDA RAM — CEO, Director | Option exercise (M): 333,333 @ $0 · Option exercise (M): 233,334 @ $0 · Option exercise (M): 333,334 @ $0 · Option exercise (M): 251,250 @ $0 · Gift (G): 200,000 @ $0 · Option exercise (M): 16,667 @ $0 · +9 more | EDGAR |
| 2024-03-15 | 4 | GRIMALDI CLAUDIA — Director | Option exercise (M): 83,333 @ $0 · Option exercise (M): 58,333 @ $0 · Option exercise (M): 100,000 @ $0 · Option exercise (M): 95,000 @ $0 · Option exercise (M): 83,333 (derivative) @ $0 · Option exercise (M): 58,334 (derivative) @ $0 · +4 more | EDGAR |
| 2024-03-15 | 4 | Moran James P — Director | Option exercise (M): 50,000 @ $0 · Option exercise (M): 33,334 @ $0 · Option exercise (M): 80,000 @ $0 · Option exercise (M): 28,500 @ $0 · Option exercise (M): 29,000 @ $0 · Option exercise (M): 33,333 (derivative) @ $0 · +5 more | EDGAR |
| 2024-03-15 | 4 | LIERMAN TERRY L — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | PRINS RICHARD K — Director | Option exercise (M): 100,000 @ $0 · Option exercise (M): 58,333 @ $0 · Option exercise (M): 100,000 @ $0 · Option exercise (M): 42,750 @ $0 · Option exercise (M): 28,500 @ $0 · Option exercise (M): 100,000 (derivative) @ $0 · +5 more | EDGAR |
Recent 8-K events — IGC Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2025-12-15 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IGC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →